ISO 13485 & GMP Certified Factory · Serving 200+ Brands Worldwide

News

Exhibitions, production upgrades, compliance certifications and new product launches.

News

Manufacturing, Supply and Three Paths for Global Partnerships

With seven subsidiaries, 54 trademarks and three patents, the Group’s international business centers on manufacturing and supply. From 2026 onward, its development will focus on custom OEM / ODM manufacturing, raw material supply and private-label delivery, serving brand owners, manufacturers and distributors with different product and market needs.

Today: Manufacturing and Supply at the Core The Group currently has seven subsidiaries, 54 trademarks and three patents. For international trade customers, however, its primary role is that of a manufacturer and supplier. Each subsidiary has a defined function. The research and development team handles formulation development, efficacy evaluation and the transfer of processes into production. The manufacturing team undertakes large-scale production of dermal fillers, anti-aging products and skincare products, supported by cleanrooms, automated filling lines and a batch traceability system. The supply chain team manages raw material procurement, incoming quality inspection and batch management. The sales team serves overseas brand owners, distributors and medical aesthetics providers, handling OEM / ODM orders and raw material supply. The Group’s own brands are primarily used to validate the feasibility of formulations and manufacturing processes. Proven solutions are then developed into a menu of customization options that customers can select directly, rather than forming the core of the Group’s international trade business. Looking Ahead: Custom Manufacturing, Raw Material Supply and Private-Label Delivery The next phase of international trade development will focus on three business lines. Custom Manufacturing Products will be selected according to the category requirements of each customer’s target market. Services will span formulation design, sample development and the preparation of registration documentation, covering two main categories: facial filling and rejuvenation. Raw Material Supply The Group will supply intermediate materials, including cross-linked hyaluronic acid gel, recombinant collagen and PLLA microspheres, to overseas brands and manufacturers. Standardized specifications and batch-to-batch consistency will be the key performance criteria. Private-Label Delivery Building on established formulations, the Group will work with customers to localize packaging and labeling, shortening the time from order placement to market launch. These three business lines address the needs of brand owners seeking differentiated products, manufacturers with their own production lines, and distributors prioritizing speed to market, respectively.

Read More

Latest News

All

Manufacturing, Supply and Three Paths for Global Partnerships

With seven subsidiaries, 54 trademarks and three patents, the Group’s international business centers on manufacturing and supply. From 2026 onward, its development will focus on custom OEM / ODM manufacturing, raw material supply and private-label delivery, serving brand owners, manufacturers and distributors with different product and market needs.

Today: Manufacturing and Supply at the Core The Group currently has seven subsidiaries, 54 trademarks and three patents. For international trade customers, however, its primary role is that of a manufacturer and supplier. Each subsidiary has a defined function. The research and development team handles formulation development, efficacy evaluation and the transfer of processes into production. The manufacturing team undertakes large-scale production of dermal fillers, anti-aging products and skincare products, supported by cleanrooms, automated filling lines and a batch traceability system. The supply chain team manages raw material procurement, incoming quality inspection and batch management. The sales team serves overseas brand owners, distributors and medical aesthetics providers, handling OEM / ODM orders and raw material supply. The Group’s own brands are primarily used to validate the feasibility of formulations and manufacturing processes. Proven solutions are then developed into a menu of customization options that customers can select directly, rather than forming the core of the Group’s international trade business. Looking Ahead: Custom Manufacturing, Raw Material Supply and Private-Label Delivery The next phase of international trade development will focus on three business lines. Custom Manufacturing Products will be selected according to the category requirements of each customer’s target market. Services will span formulation design, sample development and the preparation of registration documentation, covering two main categories: facial filling and rejuvenation. Raw Material Supply The Group will supply intermediate materials, including cross-linked hyaluronic acid gel, recombinant collagen and PLLA microspheres, to overseas brands and manufacturers. Standardized specifications and batch-to-batch consistency will be the key performance criteria. Private-Label Delivery Building on established formulations, the Group will work with customers to localize packaging and labeling, shortening the time from order placement to market launch. These three business lines address the needs of brand owners seeking differentiated products, manufacturers with their own production lines, and distributors prioritizing speed to market, respectively.

Read More

AstheMell Established to Specialize in Customized Facial Fillers and Rejuvenation Products

Established in early 2025, Aasthe Mill Bio-Medical R&D Co., Ltd. serves overseas markets through its international trade brand, AstheMell. The company specializes in customized facial fillers and rejuvenation products, offering one-stop OEM, ODM and OBM services from formulation development and packaging design to registration documentation, sampling and bulk delivery.

2025 In early 2025, the Group established Aasthe Mill Bio-Medical R&D Co., Ltd. as its research, development and customization entity for overseas markets, and launched AstheMell as its international trade brand. The company focuses on mainstream facial fillers and facial rejuvenation products for international markets. Its portfolio covers established overseas product categories, including cross-linked hyaluronic acid fillers, collagen-based implants, PLLA and PDLLA biostimulatory materials, calcium hydroxyapatite and polycaprolactone products, as well as complementary mesotherapy formulations. Built around one-stop customization, its services span formulation selection and adjustment, packaging and visual design, preparation of registration documentation for target markets, sample development and bulk delivery. The company supports OEM, ODM and OBM partnerships. In terms of regulatory qualifications, the company organizes its research, development and production processes in accordance with ISO 13485 and GMP quality systems. Relevant facial filler products have obtained CE certification, enabling the company to meet medical device market access requirements in overseas markets.

Read More
JARZAM NAD+ presentation at the MEVOS anti-aging conference

Patented NAD+ Technology Moves into Products Focused on Skin Brightening and Anti-Aging

In July 2024, the Group advanced the commercialization of its patented NAD+ anti-aging technology, focusing on skin brightening and anti-aging. The approach combines stabilization and delivery systems with ingredients targeting pigmentation pathways, creating a technical proposition for products addressing dullness, fine lines and loss of firmness, as well as customized export projects.

July 2024 In July 2024, the Group advanced the commercialization of NAD+ as a patented anti-aging ingredient, defining its product development focus as skin brightening and anti-aging. NAD+ (nicotinamide adenine dinucleotide) is a key coenzyme involved in cellular energy metabolism and DNA repair. However, its poor stability and difficulty penetrating the skin are major barriers to its application. The Group’s patented approach focuses on stabilization and delivery systems to improve NAD+ retention in formulations and enhance penetration efficiency. In product design, NAD+ is combined with ingredients that act on pigmentation pathways, addressing both dull skin tone and concerns such as fine lines and loss of firmness. This creates a positioning distinct from products focused on a single benefit. The technology has attracted attention at industry trade shows and through professional channels. It also provides a clearly defined technical selling point for subsequent customized export projects.

Read More

Growing Trademark and Patent Portfolio Provides a Foundation for Product Innovation

By December 2023, the Group had built a substantial trademark and patent portfolio spanning brand identities and filler and anti-aging technologies. With some patents granted and others under examination, these assets support formulation reuse, export compliance and technology licensing, providing a foundation for continued product development.

December 2023 By December 2023, the Group had built a substantial portfolio of trademarks and patents. Its trademarks cover names and visual identities across its brand portfolio, while its patents focus on two main areas of technology: fillers and anti-aging. These include crosslinking processes, microsphere particle size control, ingredient ratios and sustained-release structures. Some patents have been granted, while the remaining applications are under examination. These accumulated intellectual property assets provide practical business value in three areas. First, formulation reuse. The same technical solution can be adapted and reused across different brands and contract manufacturing projects, reducing the development cost of individual new products. Second, export compliance. Proprietary intellectual property can help reduce infringement risks in overseas sales and private-label supply. Third, technology licensing. Customers choosing customized services can use existing protected technical solutions directly, without having to develop separate approaches to work around them. For the Group, intellectual property at this stage is no longer a collection of isolated documents. It has become a body of technical assets that can support subsequent product iterations.

Read More

Focusing R&D on Medical Aesthetics and Launching International Customization

In November 2023, the Group focused its R&D on fillers and anti-aging products while launching customization services for overseas clients. Formulation, packaging and regulatory documentation support extended its domestic manufacturing capabilities into export markets, adding international customization as a third business line.

November 2023 In November 2023, the Group defined a clear strategic direction: concentrate its research and development on minimally invasive and non-surgical medical aesthetics, narrowing its product portfolio to fillers and anti-aging products. At the same time, it began taking on customization projects for overseas clients, extending its previously domestic-focused contract manufacturing capabilities into export markets. R&D resources were allocated around two core areas. Filler development covered hyaluronic acid, collagen and regenerative materials, with a focus on crosslinking processes, particle size control and duration of effect. Anti-aging development centered on mesotherapy combination formulations and efficacy-focused skincare, emphasizing active ingredient combinations and penetration efficiency. For its international customization business, the Group organized delivery around the practical needs of overseas clients. Its workflow covered formulation selection and adjustment, packaging design and sampling, and the preparation of registration and technical documentation in line with the regulations of each target market. This established a customization process serving overseas brand owners and distributors. At this stage, the Group expanded from two business lines, domestic contract manufacturing and proprietary brands, to three parallel lines: domestic contract manufacturing, proprietary brands and customization for overseas clients.

Read More
Ren Chengyuan at the JARZAM brand ambassador signing ceremony

JARZAM Appoints World Champions Luo Dan and Ren Chengyuan as Brand Ambassadors

In September 2022, the Group appointed world champions Luo Dan and Ren Chengyuan as JARZAM brand ambassadors. The partnership centers on brand films, training and competition content, and point-of-sale materials, using the theme of champion standards to communicate the brand’s focus on efficacy and quality.

September 2022 In September 2022, the Group signed world champions Luo Dan and Ren Chengyuan as brand ambassadors for JARZAM. Unlike the partnership with film and television personalities two years earlier, this collaboration focused on competitive athletes. Their public profiles are built on measurable achievements, while training, recovery and the management of physical condition require sustained, long-term commitment. This aligns closely with the emphasis that anti-aging products place on consistent effort and visible results. The collaboration encompasses brand films, content documenting training and competition, and point-of-sale materials. Champion standards serve as the central theme of the brand’s communications, supporting its messaging around product efficacy and quality.

Read More

Shanghai Jiazan Biotechnology Established to Focus on Skin Repair and Anti-Aging

In September 2021, the Group established Shanghai Jiazan Biotechnology Co., Ltd. to consolidate its skin repair and anti-aging research and production functions. Its work spans formulation development, efficacy evaluation and process scale-up, linking research validation with large-scale manufacturing to shorten the path from project initiation to commercial production.

September 2021 In September 2021, the Group established Shanghai Jiazan Biotechnology Co., Ltd., bringing its research, development and production functions related to skin repair and anti-aging under this entity. Its operations cover three key stages. In formulation development, the company develops formulation systems targeting impaired skin barrier function, collagen loss and photoaging. This work encompasses combinations of active ingredients, skin penetration and stability design. In efficacy evaluation, the company establishes raw material screening criteria and in vitro, ex vivo and human efficacy evaluation models, providing quantifiable data to support formulation development. In process transfer, the company carries out pilot-scale production and process validation, defining process parameters and quality standards that support consistent commercial-scale production. The Group’s manufacturing bases then use these specifications for batch production. This structure establishes a division of responsibilities across research and validation, process transfer and large-scale manufacturing within the Group, shortening the time required to take new products from project initiation to commercial production.

Read More

E-Commerce Launches Alongside OEM/ODM and Direct Supply

In early 2021, the Group launched its e-commerce operations through JD.com, Douyin, its own app and a WeChat Mini Program. Integrated product, order, inventory and membership data supported this new business alongside OEM/ODM customization and direct supply to medical aesthetic institutions.

Early 2021 In 2021, the Group formally established its e-commerce team, opened brand stores on JD.com and Douyin in stages, and completed the development and launch of its own app and WeChat Mini Program. Each sales touchpoint had a defined role. JD.com served search-driven purchases and repeat orders, while Douyin used short videos and livestreaming to drive conversions. The Group’s own app and Mini Program consolidated membership information, orders and service records, reducing reliance on traffic from third-party platforms. On the operations side, the Group integrated product, order, inventory and membership data, enabling coordinated management of online orders and warehouse dispatch. Alongside e-commerce, its B2B OEM/ODM customization business and direct supply to medical aesthetic institutions continued to develop. All three business lines shared the same production and warehousing infrastructure. Together, these platforms gave the Group multiple ways to reach consumers directly.

Read More

Building a Systematic Trademark and Patent Portfolio

In November 2020, the Group began systematically building its trademark and patent portfolio, translating manufacturing and formulation expertise into documented intellectual property. Applications covered planned brands and key filler and anti-aging technologies; most remained under examination and had not yet been granted.

November 2020 In November 2020, the Group launched a systematic initiative to build its trademark and patent portfolio. On the trademark front, in addition to the already registered JARZAM trademark, the Group submitted applications for several planned brands, covering brand names, logos and product line names. The applications spanned cosmetics, pharmaceutical preparations, medical devices and sales services, addressing both core and defensive classes to reduce the compliance costs associated with future rebranding and expansion into new product categories. Patent work focused on filler and anti-aging technologies. The Group identified potentially protectable technical features, including control of crosslinking degree and swelling ratio, monophasic gel preparation processes, PLLA microsphere particle size distribution, stability upon reconstitution of freeze-dried formulations, and the ratios used to combine active ingredients. Applications were submitted in batches. At the time, most applications were still under examination and had not yet been granted. The central task at this stage was to turn the expertise accumulated through years of manufacturing and formulation work into traceable technical documentation that could support the assertion of intellectual property rights.

Read More

Want Product or Partnership Details?

Tell us about your requirements and our team will get in touch.

Send Inquiry
滚动至顶部

LET’S TALK

Contact Us

Share your needs, and our team will be in touch.

Loading form…